

# HealthAlliance**MEDICARE**

## **PURPOSE OF THE POLICY**

To define coverage parameters for 5-HT3 receptor antagonists (ondansetron, granisetron, olasetron and palonosetron) and Emend (aprepitant)

## **STATEMENT OF THE POLICY**

Health Alliance will cover 5-HT3 receptor antagonists and aprepitant as described below:

## **PROCEDURES**

### **1. Criteria for coverage**

- 1.1 Ondansetron (Zofran®), granisetron (Kytril®), dolasetron (Anzemet®), aprepitant (Emend®), palonosetron (Aloxi®), will be covered for all FDA indications for new starts only.